Equities

Immunovant Inc

IMVT:NSQ

Immunovant Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)26.87
  • Today's Change0.33 / 1.24%
  • Shares traded523.43k
  • 1 Year change-17.77%
  • Beta0.6831
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments635377494
Total Receivables, Net5.500.8913
Total Inventory------
Prepaid expenses25276.25
Other current assets, total------
Total current assets666404513
Property, plant & equipment, net0.601.512.63
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets666406516
LIABILITIES
Accounts payable7.161.3519
Accrued expenses414226
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.020.350.17
Total current liabilities494345
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total00.051.22
Total liabilities494346
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1,442928825
Retained earnings (accumulated deficit)(826)(566)(355)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.910.850.40
Total equity618362470
Total liabilities & shareholders' equity666406516
Total common shares outstanding146130116
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.